National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 6) (Cth)
PB 105 of 2021
National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 6)
I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 28 September 2021
NIKOLAI TSYGANOV
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021) 2
1 Name
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 6).
This instrument may also be cited as PB 105 of 2021.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 October 2021. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under section 85B of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021)
1 Schedule 1, omit entry for Acarbose
2 Schedule 1, entry for Cyproterone
Omit
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Androcur | 20 | 13.32 | 15.55 |
| 50 | ‑ | 34.36 | ||||
| Tablet containing cyproterone acetate 100 mg | Oral | Androcur‑100 | 50 | 51.88 | 53.19 |
Substitute
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Androcur | 50 | ‑ | 34.36 |
| Tablet containing cyproterone acetate 100 mg | Oral | Androcur‑100 | 50 | 51.88 | 53.19 |
3 Schedule 1, entry for Dutasteride
(a)omit from the column headed “Determined Price”: 15.50 substitute: 13.86
(b)omit from the column headed “Claimed Price”: 22.01 substitute: 19.68
4 Schedule 1, entry for Dutasteride with tamsulosin
(a)omit from the column headed “Determined Price”: 18.29 substitute: 16.65
(b)omit from the column headed “Claimed Price”: 21.55 substitute: 19.62
5 Schedule 1, entry for Ezetimibe
(a)omit from the column headed “Determined Price”: 10.83 substitute: 9.57
(b)omit from the column headed “Claimed Price”: 13.62 substitute: 12.04
6 Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)
(a)omit from the column headed “Determined Price”: 11.79 substitute: 10.60
(b)omit from the column headed “Claimed Price”: 14.58 substitute: 13.11
7 Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)
(a)omit from the column headed “Determined Price”: 13.24 substitute: 12.05
(b)omit from the column headed “Claimed Price”: 16.03 substitute: 14.59
8 Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)
(c)omit from the column headed “Determined Price”: 12.88 substitute: 11.75
(d)omit from the column headed “Claimed Price”: 15.67 substitute: 14.30
9 Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)
(a)omit from the column headed “Determined Price”: 13.78 substitute: 12.69
(b)omit from the column headed “Claimed Price”: 16.57 substitute: 15.26
10 Schedule 1, entry for Fluoxetine
Omit
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Prozac 20 | 28 | 3.45 | 4.55 |
| Tablet, dispersible, 20 mg (as hydrochloride) | Oral | Prozac Tab | 28 | 3.45 | 4.55 |
Substitute
| Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Prozac 20 | 28 | 3.45 | 4.55 |
11 Schedule 1, after entry for Moclobemide in the form Tablet 300 mg
Insert
| Modafinil | Tablet 100 mg | Oral | Modavigil | 60 | 88.49 | 93.49 |
12 Schedule 1, after entry for Ranitidine in the form Tablet 300 mg (as hydrochloride)
Insert
| Rasagiline | Tablet 1 mg (as mesilate) | Oral | Azilect | 30 | 69.38 | 74.38 |
13 Schedule 1, entry for Sertraline
Omit
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Zoloft | 30 | 1.57 | 6.97 |
Substitute
| Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Zoloft | 30 | 1.57 | 6.97 |
| Tablet 100 mg (as hydrochloride) | Oral | Zoloft | 30 | 1.57 | 6.97 |
0
0
0